Major Histocompatibility Complex (MHC) in Health and Disease 2022
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 25736
Special Issue Editors
Interests: immunogenetics and biology of the major histocompatibility complex; genomics; retroelements
2. School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Crawley, WA 6009, Australia
Interests: immunogenetics and biology of the major histocompatibility complex; genomics; retroelements
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The major histocompatibility complex (MHC) antigen presenting molecules consist of two primary classes of glycoproteins that bind peptides derived from intracellular or extracellular antigens and play an integral role in adaptive and innate immune defense systems. They are present in all classes of jawed vertebrates. The MHC genes are polygenic and encode a set of MHC molecules with different ranges of peptide-binding specificities that can be divided into MHC class I and MHC class II depending on their structure and phylogeny. Typically, species have several highly polymorphic genes of both class I and class II, so that there are multiple variants of those genes within the population. MHC haplotypes are extended ancestral blocks of particular combinations of MHC alleles that provide coherent genetic information concerning diversity, inheritance of traits, disease susceptibility/severity, and responses to vaccines and therapy.
The MHC classical class I molecules are expressed on the cell surface of all nucleated cells including neuronal cells in the brain, and they can present peptides derived from intracellular proteins or cellular-infected viral proteins to circulating CD8+ cytotoxic T-cells. The MHC class I molecules can also serve as inhibitory ligands for natural killer (NK) cells. In comparison, the MHC class II genes encode for cell-surface glycoproteins that bind extracellular peptides and present them to circulating CD4+ T helper cells. The expression of MHC class II genes is a characteristic of professional antigen-presenting cells such as dendritic cells, macrophages, and B cells, but expression can also be found in several other cell types. The term MHC stems historically from its role in graft rejection and tissue compatibility within donor–recipient pairs. The extensive polymorphism between the MHC molecules probably protects populations from different invading pathogens, and yet, in the clinic, it adds to the difficulty of finding matched pairs for successful transplantation outcomes.
The MHC genes, haplotypes, and polymorphic molecules are investigated continuously due to their crucial role in the regulation of innate and adaptive immune responses; the pathogenesis of numerous infectious and/or autoimmune diseases; brain development and plasticity; olfaction; therapeutic vaccinations and T cell-based immunotherapy; and the compatibility of grafted tissue, which also concerns potential graft-versus-host disease involving hematopoietic stem cell transplants. Recent reports describe a role for neuronal MHC-I in synaptic plasticity, brain development, axonal regeneration, neuroinflammatory processes, and immune-mediated neurodegeneration. In humans, the MHC (HLA) genes are part of the supra-locus on chromosome 6p21 known as the human leukocyte antigen (HLA) system. This genomic complex consists of more than 300 genes, some located closely together as haplotype blocks and involved in inflammatory and immune-response, heat shock, and complement cascade systems; cytokine signalling; and the regulation of various aspects of cellular development, differentiation, and apoptosis. Additionally, there are many putative microRNA and long-noncoding RNA loci within the HLA genomic region that may be expressed by different cell types and play a role in the regulation of immune-response genes and in the etiology of numerous diseases.
This proposed Special Issue of the MHC in Health and Disease is a follow-up to our first edition in 2019 where we published eighteen articles including one commentary, five reviews, eleven research articles, and one communication covering a broad range of topics on the genomic diversity of the MHC regulatory system in various vertebrate species in health and disease including structure and function; MHC class I, II, and III genes; antigen presentation; innate and adaptive immunity; neurology; transplantation; haplotypes; alleles; infectious and autoimmune diseases; fecundity; conservation; lineage and evolution. Taken together, these articles helped to further demonstrate the immense complexity and diversity of the MHC structure and function within and between different vertebrate species in regulating innate and adaptive immunity. [https://www.mdpi.com/journal/cells/special_issues/major_histocompatibility_complex].
The aim of this second edition is to continue and expand our examination of the polymorphic MHC class I and class II genes, haplotypes, and molecules with an added focus on their cellular functions, molecular interactions and immunity-related networks in health and disease, together with self and non-self recognition, and their role in the susceptibility and resistance to SARS-CoV-2 infections and associated COVID-19 symptoms.
Dr. Johannes M. Dijkstra
Dr. Jerzy K. Kulski
Dr. Nianzhi Zhang
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- MHC
- HLA
- function
- structure
- innate and adaptive immunity
- autoimmunity
- antigen presentation
- disease
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.